Find Funding Opportunities

This Notice is a Request for Information (RFI) on approaches NIH can take to promote greater equity in global health research, particularly research that engages scientists in low and middle-income countries (LMICs) (REF).

The purpose of this Notice is to inform potential applicants about an area of special interest to NINDS in research to develop or substantially modify existing cutting-edge tools that will advance prenatal and/or pediatric hydrocephalus research. Applications should aim to transform the field of prenatal and/or pediatric hydrocephalus research by generating tools including animal and cell models, novel methods and innovative technologies that will be widely used throughout the neuroscience community to understand disease mechanisms and/or developing therapeutics.

The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to encourage applications proposing to test multilevel strategies and interventions to improve the uptake of evidence-based screening services across the lifespan and in diverse populations including, but not limited to, those experiencing health disparities and those that have been underserved.

The Office of Disease Prevention (ODP) and participating National Institutes of Health (NIH) Institutes, Centers, and Offices (ICs) are issuing this Notice of Special Interest (NOSI) to solicit applications proposing to strengthen the evidence base for preventive screening services where the evidence is lacking, of poor quality, conflicting, or the balance of benefits and harms cannot be determined.

The purpose of this notice is to inform applicants of a change to the Key Dates for PAR-20-122 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development of Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)". An additional receipt date has been added to this FOA.

The purpose of this notice is to inform applicants of a change to the Key Dates for PAR-20-111 "Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional)". An additional receipt date has been added to this FOA.

The purpose of this notice is to correct an error in PAR-21-056 which incorrectly states that "Foreign components, as defined in the NIH Grants Policy Statement, are not allowed." As this should be corrected to reflect that Foreign components are allowed. This aligns with the companion PARs which all allow foreign components.

The purpose of this notice is to inform the community of the early termination of RFA-NS-21-015 "HEAL Initiative: Team Research for Initial Translational Efforts in Non-addictive Analgesic Therapeutics Development (U19 Clinical Trial Not Allowed)" and it's reissuance as RFA-NS-22-052

The purpose of this notice is to extend the response date for NOT-NS-22-044 "BRAIN Initiative: Request for Information (RFI) on Industry Collaboration in Development and Dissemination of Non-Invasive Brain Imaging Technologies".

The National Institute of Neurological Disorders and Stroke (NINDS) and the Office of the Director, National Institutes of Health (OD),intend to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for the conduct of scientific research utilizing data from expanded access (EA) to investigational drugs or biological products. These applications will target intermediate size populations of patients living with amyotrophic lateral sclerosis (ALS) who are not otherwise eligible for clinical trials for the diagnosis, mitigation, treatment, or cure of ALS ("intermediate EA protocol for ALS"). Providing the investigational drug or biological product under an intermediate EA protocol for ALS must not interfere with the initiation, conduct, or completion of clinical investigations that could support marketing approval, or otherwise compromise the potential development of medical products for the diagnosis, mitigation, treatment, or cure of ALS. Eligible applicants are clinical trial sites that participate in a phase 3 clinical trial supported by a United States (U.S.) small business concern (as defined in section 3(a) of the Small Business Act (15 U.S. C. 623(a)) that is also the U.S. Food and Drug Administration (FDA) designated sponsor of a drug or biological product for ALS that is the subject of an Investigational New Drug Application (IND). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. The FOA is expected to be published in May 2022 with an expected application due date in June 2022. This FOA will utilize the U01 activity code. Details of the planned FOA are provided below.